Plexxikon Inc., of Berkeley, Calif., said its acquisition by Daiichi Sankyo Co. Ltd., of Tokyo, was completed. Under the terms of the deal, Plexxikon shareholders will receive $805 million up front, with near-term milestones associated with approval of melanoma drug PLX4032 totaling an additional $130 million.